about
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinoma.Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer.Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.Establishment and validation of circulating tumor cell-based prognostic nomograms in first-line metastatic breast cancer patients.Trends in cancer-targeted antibody-drug conjugates.Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know?Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).High purity microfluidic sorting and analysis of circulating tumor cells: towards routine mutation detection.Circulating tumor cells: clinical validity and utility.HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.Time-Dependent Prognostic Impact of Circulating Tumor Cells Detection in Non-Metastatic Breast Cancer: 70-Month Analysis of the REMAGUS02 Study.Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).The Genomic Landscape of Male Breast Cancers.Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.Circulating tumor cell count and thrombosis in metastatic breast cancer.Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa.Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.Response to dual HER2 blockade in a patient with HER3-mutant metastatic breast cancer.FISH-in-CHIPS: A Microfluidic Platform for Molecular Typing of Cancer Cells.FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool.[Breast cancer screening: On our way to the future].Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.Clinical utility of circulating tumor cells in metastatic breast cancer.Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.Meningeal carcinomatosis in HER2-overexpressing breast cancers.Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumaOutlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors.Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer.Disseminated tumor cells predict efficacy of regional nodal irradiation in early stage breast cancer[Circulating tumour DNA: Current detection methods, use in radiotherapy and future development][Circulating tumor cells and breast cancer: detection techniques and clinical results]Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapySingle Droplet Digital Polymerase Chain Reaction for Comprehensive and Simultaneous Detection of Mutations in Hotspot Regions
P50
Q33372916-AAC3884E-9355-40FD-A02C-5843947BEC96Q34407319-7B737AF1-55DE-48EB-BA1F-38B1E58F9D1BQ34796583-68CAAC1F-55D5-4CA6-97FD-DCB4BC731D3DQ35533590-346F9A95-858D-4F84-87AE-6D917CEA2F1AQ36359821-12E5B016-D099-4313-8A1B-9EC37A571662Q36869787-737F03B7-76A1-4182-BD8D-8FA999EF787BQ38162127-2A19D2B8-1735-44DB-A2EE-98A54912F8D3Q38390966-E5F55925-F3C8-4EF4-8F73-EE42FEC87A6AQ38759027-DA9F1BC1-A4B8-4FA2-8757-448345CFBE18Q38794688-7296C6FB-98AD-459D-A5BD-388C2E1525A2Q38800053-AED2DF76-FEAA-45BD-B406-6DA4C0E77925Q38894358-7944585B-189D-4E4A-BE89-5EF2BAEEB56CQ39151285-B5FEDD45-2C0B-48EA-8492-1BA44F814949Q40483016-8B112FC2-63FA-4458-A892-03BA5B765977Q41094757-066585EB-9A35-474A-9FFD-04AA4F675C48Q41541911-933E6858-19E4-40C0-B5DA-BE633838074CQ41739963-26F12FF0-E2DF-4947-97E9-B99F23E9A585Q42428880-425A69A7-24BB-4DDB-885C-14262E27D623Q43127349-4435806F-3053-4448-A2A0-3A8A29D2073AQ46157402-E3B434CB-A39E-4CE0-9681-3E9FF93F9025Q47415917-1331F614-E335-45EF-84C4-01708ADDC523Q48286587-A8CDC4CF-614C-46D5-BB98-647296BF7198Q48549094-55040A2D-EB0E-47F6-81BB-423F7197B6DEQ49061268-41C62DD4-E743-454F-9F0B-741E49C978CEQ51026625-25053C6E-190B-4E33-9ACA-4FFC1B30E06DQ51062308-DD01854A-1C4E-4337-994B-AD3543687CF0Q51503743-499D8ABF-6D86-4961-AF72-44F1C75A0641Q53050368-60BC911B-765B-4F74-991F-D1E56EB666A9Q53073587-C6434086-6DFC-476A-AE97-492B32B18DE0Q53546262-11FC6D9A-0805-4180-B11A-3514F7C2B9EFQ54307676-96DDA100-9C26-48FA-A9C5-FAED30E99697Q54774390-91F4AA0E-44F5-4310-A715-06652EE5B78FQ55004552-63356DE1-17FF-45FD-9B91-8B47620F80C3Q55135864-58AD4318-77EE-4200-A8A4-972E17F32F08Q55476083-B552FE41-3362-43D9-8BA9-621FAE397432Q57037175-329070A6-BC73-46F8-A99B-33499790C761Q57135335-23913111-7516-4A08-9123-28C9D67CA6EFQ57142820-4004EBE2-6958-49B0-B41F-B07E60E81BF4Q57143867-FF4017FE-D12E-47C2-A7D2-F4967B3277B5Q57492264-4FA5990A-5FFB-466E-8AAE-2E1ECB9C3C1F
P50
description
researcher ORCID ID=0000-0001-5932-8949
@en
name
F C Bidard
@en
F C Bidard
@nl
type
label
F C Bidard
@en
F C Bidard
@nl
prefLabel
F C Bidard
@en
F C Bidard
@nl
P108
P106
P31
P496
0000-0001-5932-8949